

Cyrielle Caussy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1480080/publications.pdf>

Version: 2024-02-01

43
papers

3,478
citations

279487

23
h-index

288905

40
g-index

45
all docs

45
docs citations

45
times ranked

5004
citing authors

#	ARTICLE	IF	CITATIONS
1	History of bariatric surgery and COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. <i>Obesity</i> , 2022, 30, 599-605.	1.5	7
2	Short echo time dual-frequency MR Elastography with Optimal Control RF pulses. <i>Scientific Reports</i> , 2022, 12, 1406.	1.6	2
3	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	1.9	9
4	Undernourished patients do not have increased risk of severe COVID-19 outcomes. <i>Clinical Nutrition Open Science</i> , 2022, , .	0.5	0
5	PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4305.	1.8	28
6	Editorial: screening for hepatocellular carcinoma in <sc>NAFLD</sc> â€”towards abbreviated <sc>MRI</sc> alternative in patients with obesity?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1210-1211.	1.9	2
7	Letter: nonâ€invasive prediction models to exclude cirrhosis in <sc>NAFLD</sc> â€”not everyone fits the mould. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 182-183.	1.9	0
8	Relationship between obesity and severe <sc>COVID</sc>-19 outcomes in patients with type 2 diabetes: Results from the <sc>CORONADO</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 391-403.	2.2	69
9	Harmonic wideband simultaneous dualâ€frequency MR Elastography. <i>NMR in Biomedicine</i> , 2021, 34, e4442.	1.6	2
10	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. <i>Current Diabetes Reports</i> , 2021, 21, 15.	1.7	78
11	BMI and pneumonia outcomes in critically ill COVID-19 patients: An international multicenter study. <i>Obesity</i> , 2021, 29, 1477-1486.	1.5	24
12	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. <i>Diabetes and Metabolism</i> , 2021, 47, 101272.	1.4	18
13	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1253-1266.	1.4	9
14	Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 741-743.	2.4	27
15	Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 744-746.e1.	2.4	26
16	Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imagingâ€Proton Density Fat Fraction as the Standard. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1842-1850.e6.	2.4	37
17	Magnetic resonanceâ€based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00134.	1.0	11
18	Non-alcoholic fatty liver disease and chronic kidney disease: renal benefit with liver stiffness assessment?. <i>Diabetes and Metabolism</i> , 2020, 46, 259-260.	1.4	0

#	ARTICLE	IF	CITATIONS
19	La stéatopathie dysmétabolique ou NASH: faut-il dépister les patients à haut risque atteints de diabète de type 2 ou d'obésité? Nutrition Clinique Et Metabolisme, 2020, 34, 122-129.	0.2	0
20	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut, 2020, 69, 1877-1884.	6.1	127
21	A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metabolism, 2020, 32, 878-888.e6.	7.2	167
22	Obesity is Associated with Severe Forms of COVID-19. Obesity, 2020, 28, 1175-1175.	1.5	130
23	Prevalence of obesity among adult inpatients with COVID-19 in France. Lancet Diabetes and Endocrinology, 2020, 8, 562-564.	5.5	194
24	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clinical Gastroenterology and Hepatology, 2019, 17, 630-637.e8.	2.4	254
25	Should We Screen High-Risk Populations for NAFLD?. Current Hepatology Reports, 2019, 18, 433-443.	0.4	6
26	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 2140.	2.4	0
27	Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. Hepatology, 2019, 70, 127-141.	3.6	21
28	A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nature Communications, 2019, 10, 1406.	5.8	218
29	Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut, 2019, 68, 1884-1892.	6.1	48
30	Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Alimentary Pharmacology and Therapeutics, 2019, 49, 183-193.	1.9	80
31	Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1974-1982.e7.	2.4	46
32	Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology, 2018, 68, 763-772.	3.6	299
33	Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 307-310.e2.	0.6	113
34	An artificial neural network to predict resting energy expenditure in obesity. Clinical Nutrition, 2018, 37, 1661-1669.	2.3	32
35	Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology, 2018, 67, 1348-1359.	3.6	250
36	New rare genetic variants of LMF1 gene identified in severe hypertriglyceridemia. Journal of Clinical Lipidology, 2018, 12, 1244-1252.	0.6	19

#	ARTICLE	IF	CITATIONS
37	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2017, 25, 1054-1062.e5.	7.2	748
38	EASLâ€“EASDâ€“EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?. <i>Diabetologia</i> , 2017, 60, 1218-1222.	2.9	95
39	Alterations in plasma triglycerides lipolysis in patients with history of multifactorial chylomicronemia. <i>Atherosclerosis</i> , 2017, 265, 22-28.	0.4	12
40	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. <i>Journal of Clinical Investigation</i> , 2017, 127, 2697-2704.	3.9	137
41	Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3â€²UTR variant SstI. <i>Atherosclerosis</i> , 2016, 255, 6-10.	0.4	6
42	Multiple microRNA regulation of lipoprotein lipase gene abolished by 3â€²UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter. <i>Atherosclerosis</i> , 2016, 246, 280-286.	0.4	23
43	An APOA5 3â€² UTR Variant Associated with Plasma Triglycerides Triggers APOA5 Downregulation by Creating a Functional miR-485-5p Binding Site. <i>American Journal of Human Genetics</i> , 2014, 94, 129-134.	2.6	58